CAS NO: | 1431698-47-3 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 493.45 |
---|---|
Formula | C24H26Cl2N2O3S |
CAS No. | 1431698-47-3 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: ~25mg/mL |
Water: N/A | |
Ethanol: N/A | |
Chemical Name | (E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide phosphate |
Synonyms | KN-92 HCl; KN-92; KN 92; KN92 |
In Vitro | In vitro activity: KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM). KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cell. Cell Assay: KN-92 is an inactive derivative of KN-93. It is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM). KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM). KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cell. |
---|---|
In Vivo | |
Animal model | |
Formulation & Dosage | |
References | World J Gastroenterol. 2007 Mar 7;13(9):1445-8; Cancer Biol Ther. 2010 Feb;9(3):224-35. |